 SAN DIEGO, Oct. 11, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical data for repotrectinib from the ongoing Phase 12 CARE study in pediatric and young adult patients with advanced solid tumors harboring ALK, ROS1 or NTRK alterations at the virtual 53rd Congress of the International Society of Paediatric Oncology SIOP being held October 21-24. 